We next analysed cervical samples from yet unaffected BRCA1 (n = 57) and BRCA2 (n = 53) mutation carriers (i.e. women who have not yet developed breast and/or ovarian cancer) and 114 healthy controls. This evidence concerns the gene BRCA1 and ovarian cancer.